CoronaVac efficacy data from Turkey
- PMID: 34801104
- PMCID: PMC8601678
- DOI: 10.1016/S0140-6736(21)02288-1
CoronaVac efficacy data from Turkey
Conflict of interest statement
BJC reports honoraria from AstraZeneca, GlaxoSmithKline, Moderna, Roche, and Sanofi Pasteur and is supported by the AIR@innoHK programme of the Innovation and Technology Commission of the Hong Kong Government. MEM is supported by the Research Grants Council of Hong Kong.
Comment in
-
CoronaVac efficacy data from Turkey - Authors' reply.Lancet. 2021 Nov 20;398(10314):1874. doi: 10.1016/S0140-6736(21)02286-8. Lancet. 2021. PMID: 34801106 Free PMC article. No abstract available.
Comment on
-
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.Lancet. 2021 Jul 17;398(10296):213-222. doi: 10.1016/S0140-6736(21)01429-X. Epub 2021 Jul 8. Lancet. 2021. PMID: 34246358 Free PMC article. Clinical Trial.
References
-
- Palacios R, Batista AP, Albuquerque CSN, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV Study. SSRN. 2021 doi: 10.2139/ssrn.3822780. published online April 11. (preprint). - DOI
-
- Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–1211. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources